Symposium on Clinical Pharmacology. Biochemical Pharmacology

Content: 
Front Matter, Page ifc3
Copyright, Page ifc4
SYMPOSIUM ON CLINICAL PHARMACOLOGY, Page i
INTRODUCTORY REMARKS, Page iv
PHARMACOKINETICS AND DRUG EFFECT, Pages 1-8
ABSORPTION, PROTEIN BINDING, DISTRIBUTION AND EXCRETION OF ANTINEOPLASTIC DRUGS, Pages 9-20
FACTORS AFFECTING BIOTRANSFORMATION AND ACTIVITY OF ANTITUMOR DRUGS, Pages 21-33
THE PRODUCT OF CONCENTRATION AND TIME, Pages 35-45
TRANSPORT OF TUMOR-INHIBITORY AGENTS ACROSS CELL MEMBRANES, Pages 47-50
PHARMACOLOGICAL CONSIDERATIONS IN THE CHEMOTHERAPY OF CENTRAL NERVOUS SYSTEM TUMORS, Pages 51-56
DESCRIPTIVE AND OPERATIONAL CYTOKINETICS, Pages 57-69
ROLE OF ENZYMATIC ACTIVATION AND INACTIVATION IN DRUG SELECTIVITY, Pages 71-82
GENERAL MECHANISMS OF CLINICAL RESISTANCE TO CANCER CHEMOTHERAPY, Pages 83-88
MECHANISMS OF CLINICAL DRUG RESISTANCE TO ALKYLATING AGENTS, Pages 89-100
RESISTANCE TO FOLIC ACID ANTAGONISTS - CLINICAL ASPECTS, Pages 101-106
RESISTANCE TO PURINE ANALOGS, Pages 107-117
CLINICAL RESISTANCE TO ANTIPYRIMIDINE ANTICANCER DRUGS, Pages 119-127
BIOCHEMICAL AND PHARMACOLOGICAL PRINCIPLES OF COMBINATION CHEMOTHERAPY, Pages 129-139
THERAPEUTIC SYNERGISM IN ANIMAL MODELS – INCREASED ANTITUMOR SPECIFICITY RESULTING FROM DIMINISHED TOXICITY FOR THE HOST, Pages 141-150
SCHEDULE-DEPENDENT SYNERGISM AND ANTAGONISM BETWEEN METHOTREXATE AND ASPARAGINASE, Pages 151-161
NEW EXPERIMENTAL DRUG COMBINATIONS WITH POTENTIAL CLINICAL UTILITY, Pages 163-176
NEW COMBINATIONS IN THE TREATMENT OF LUNG CANCER, Pages 177-182
CHEMOTHERAPY OF METASTATIC SARCOMAS USING COMBINATIONS WITH ADRIAMYCIN, Pages 183-192
BLEOMYCIN AND PHLEOMYCIN - RECEPTIVITY OF TARGET SITES, Pages 193-206
ADRIAMYCIN-DAUNORUBICIN CELLULAR PHARMACODYNAMICS, Pages 207-216
THE VINCA ALKALOIDS, Pages 217-223
REACTIONS AND EFFECTS OF NITROSOUREAS, Pages 225-232
CONCLUDING REMARKS, Pages 233-236